SCHEMBL30204367

SCHEMBL30204367

COc1c(Br)ccc(C(C)=O)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
MAPT P10636 5/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 2/20 0.39
HTT P42858 2/20 0.37
TSHR P16473 1/20 0.37
APOBEC3A P31941 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
ABCB1 P08183 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
PTPN1 P18031 1/20 0.35
MEN1 O00255 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17040892 0.86 ALDH1A1 (0.40) ALOX5APFEN1MAPTRAB9ASMN1; SMN2
SCHEMBL592060 0.86 HSD17B10 (0.50) ALOX5APFEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL3585020 0.84 SOS1 (0.43) ALOX5APFEN1MAPTRAB9ASMN1; SMN2
SCHEMBL30039045 0.82 ALDH1A1 (0.40) MAPTALDH1A1CYP3A4HPGDMAPK1
SCHEMBL116280 0.81 CES2 (0.45) MAPTALDH1A1CYP3A4HPGDMAPK1
SCHEMBL532654 0.80 MAPT (0.51) MAPTRAB9ASMN1; SMN2ALDH1A1CYP3A4
SCHEMBL30884766 0.80 MAPT (0.51) MAPTRAB9ASMN1; SMN2ALDH1A1CYP3A4
SCHEMBL31535247 0.79 ALOX5AP (0.37) ALOX5APFEN1MAPTRAB9ASMN1; SMN2
SCHEMBL23361257 0.79 ALDH1A1 (0.49) MAPTSMN1; SMN2ALDH1A1CYP3A4HPGD
SCHEMBL17041239 0.76 ALDH1A1 (0.41) MAPTRAB9ASMN1; SMN2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
CN-117858877-A C-linked inhibitors of ENL/AF9 YEATS 桥梁药品有限公司 2024-04-09 CN disclosed
EP-4337662-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS Bridge Medicines (US) 2024-03-20 EP disclosed
WO-2022240830-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 ALOX5AP 3247/4885FEN1 3818/4885MAPT 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.